SAR7334

inhibits TRPC6 channels; structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Aherrahrou, Redouane: 1 article (01/2021)
2.	Cepele, Ganildo: 1 article (01/2021)
3.	Civelek, Mete: 1 article (01/2021)
4.	Dichgans, Martin: 1 article (01/2021)
5.	Dietrich, Alexander: 1 article (01/2021)
6.	Erdmann, Jeanette: 1 article (01/2021)
7.	Flockerzi, Veit: 1 article (01/2021)
8.	Kastrati, Adnan: 1 article (01/2021)
9.	Kessler, Thorsten: 1 article (01/2021)
10.	Mann, Matthias: 1 article (01/2021)

1.	Neointima 01/01/2021 - "While Trpc6-/- mice presented reduced neointima formation compared to wild-type mice (1.44 ± 0.39 vs. 2.16 ± 0.48, P = 0.01), activating or repressing TRPC6 in human vascular smooth muscle cells resulted in increased [vehicle 156.9 ± 15.8 vs. 1-oleoyl-2-acetyl-sn-glycerol 179.1 ± 8.07 (103 pixels), P = 0.01] or decreased migratory capacity [vehicle 130.0 ± 26.1 vs. SAR7334 111.4 ± 38.0 (103 pixels), P = 0.04], respectively. "
2.	Hypoxia (Hypoxemia) 02/19/2023 - "SAR7334 (1 µM), an antagonist of TRPC3 and TRPC6, reduced the basal and [Ca2+]i overload caused by hypoxia. "